Orsini Specialty Pharmacy Selected By PTC Therapeutics As A Limited Distribution Partner For EMFLAZA® (deflazacort)

 

ELK GROVE VILLAGE, Ill., Oct. 7, 2020 /PRNewswire/ -- Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced today that it has been selected by PTC Therapeutics, Inc. as a limited distribution partner for EMFLAZA® (deflazacort). EMFLAZA is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older See Full Prescribing Information. Orsini is the only specialty pharmacy with access to all DMD therapies.

Primarily affecting males, DMD is a rare and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death in the mid-twenties due to heart and respiratory failure. It is a progressive muscle disorder caused by the lack of functional dystrophin protein. Dystrophin is critical to the structural stability of skeletal, diaphragm, and heart muscles. Patients with Duchenne can lose the ability to walk as early as age ten, followed by loss of the use of their arms. Duchenne patients subsequently experience life-threatening lung complications, requiring the need for ventilation support, and heart complications in their late teens and twenties. More information regarding Duchenne is available through the Muscular Dystrophy Association and the Parent Project Muscular Dystrophy. Additionally, information and resources are available at www.duchenneandyou.com.  

"We are excited about our partnership with PTC Therapeutics, Inc. and adding EMFLAZA to the therapies we provide to patients with DMD," said Mike Fieri, Orsini Chief Executive Officer. "High touch care coordination and collaboration drive our unique specialty pharmacy care model, and our highly experienced DMD Care Team is focused on getting patients on therapy quickly and providing personalized and compassionate care throughout their journey."

About Orsini Specialty Pharmacy

Providing patients with comprehensive and compassionate care since 1987, Orsini is a leading, independent specialty pharmacy focused on rare diseases and gene therapies. Orsini's high touch care model is centered around experienced, therapy-specific care teams who provide personalized care to patients based on their specific condition and treatment. The company's comprehensive solutions include medication adherence programs, data analytics, customized manufacturer programs and nationwide nursing coverage for convenient in-home infusion services. Headquartered in Elk Grove Village, IL, Orsini Specialty Pharmacy holds accreditations with the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC, NABP, and most recently was awarded ACHC's Distinction in Rare Diseases and Orphan Drugs.

About PTC Therapeutics, Inc.

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.

For more information about Orsini's services, contact us at 847-734-7373 ext. 545, e-mail us at Orsini@orsinihc.com, or visit http://orsinispecialtypharmacy.com.  

For more information about EMFLAZA, visit http://emflaza.com.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/orsini-specialty-pharmacy-selected-by-ptc-therapeutics-as-a-limited-distribution-partner-for-emflaza-deflazacort-301146802.html

SOURCE Orsini Specialty Pharmacy

 

Back to news